FDA Publishes Guidance on ANDA Submissions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Publishes Guidance on ANDA Submissions


FDA has released two guidance documents relating to the submission of abbreviated new drug applications (ANDAs). In the guidance documents, FDA explains requirements in regards to the Generic Drug User Fee Amendments of 2012 (GDUFA).

Guidance for Industry, ANDA Submissions—Amendments and Easily Correctable Deficiencies Under GDUFA, explains how the performance metric goals established as part the GDUFA apply to ANDAs to assist applicants preparing to submit to FDA amendments to ANDAs or prior approval supplements (PASs) under section 505(j) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act).  

The guidance describes the Tier system for the different types of amendments and the request for reconsideration process for FDA classification decisions. The guidance explains how different types of amendments may affect the application’s original review dates, as well as FDA’s performance metric goals based on the different amendment Tiers and the process for submitting amendments.

FDA states that the finalized guidance will replace the December 2001 Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications guidance in consideration of the new amendment review Tier system and performance goals under GDUFA.

The second guidance, ANDA Submissions—Prior Approval Supplements Under GDUFA, Draft Guidance, explains how the GDUFA relates to PAS submissions. FDA intends for the guidance to assist applicants preparing to submit PASs and amendments to PASs for ANDAs submitted under section 505(j) of the FD&C Act.

The guidance describes how the GDUFA performance metric goals apply to a PAS subject to the refuse-to-receive standards, a PAS that requires an inspection, a PAS for which an inspection is not required, an amendment to a PAS, and other PAS-related matters. The guidance also describes performance metric goals outlined in the GDUFA Commitment Letter and clarifies how FDA will handle a PAS and amendments to a PAS for an ANDA subject to the GDUFA performance metric goals.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here